$Moderna, Inc.(MRNA)$ $Pfizer(PFE)$ $SELLAS Life Sciences Group Inc.(SLS)$ $Johnson & Johnson(JNJ)$ Breaking news here. Hopefully some of you bought the dip last week. Big breakout expected next week, starting Monday. Mark this post. Major data came out Saturday, October 24. Honestly, I'm surprised investors aren't talking about it yet. This is a big deal. $AbCellera Biologics(ABCL)$ — new Phase 3 data for T-cell engagers. Amgen just released detailed results from its Phase 3 DeLLphi-305 trial at ESMO 2026, and the numbers are impressive. 58% reduc
$Moderna, Inc.(MRNA)$ $Pfizer(PFE)$ $SELLAS Life Sciences Group Inc.(SLS)$ $Eli Lilly(LLY)$ AbCellera has a major T-cell engager partnership with Jazz Pharmaceuticals targeting gastrointestinal cancers and other solid tumors. The deal includes $84M in committed upfront payments, up to $792M in potential additional payments per program, and up to $2.376 billion across three programs, plus potential royalties. Amgen's results provide powerful clinical validation for T-cell engagers in solid tumors, although they don't prove anything about AbCellera's specific candidates. Big Pharma is investing billions in
$IREN Ltd(IREN)$ Day traders, swing traders, and shorts keep messing up the momentum. Even after they exit, they keep coming back. Can you guys just go long for the upcoming run up?
With the earnings report coming up in a few hours, this week's options are suggesting a trading range of $64 to $75.50. The put/call volume ratio sits at .91, which is slightly bullish, and the put/call OI ratio at .63 is more bullish. IV is at 131%, which is very expensive. The stock dropped after the last 5 earnings reports. There are 52 analysts with an average target of 91.13, implying 31.51% upside. Bull case: Netflix's scale advantage, expanding ad-supported tier, and high-margin operating model position it for sustained operational leverage and long-term EPS growth. Bear case: decelerating core organic engagement, high bid costs for live broadcasting rights, and C-suite leadership turnover present near-term execution and valuation risks. Initially I was thinking a bear bet, but afte
$IREN Ltd(IREN)$ People buy a stock and expect it to go up right away, then panic when it doesn't. Let the trade work itself out. The market will correct and we'll be at $50+ in no time.
$SK hynix(SKHY)$ Really like the valuation here. Forward P/E ratio of 4. No need for anything extra, just staying on track at that forward P/E of 4 with no growth works out to a 25% annual gain.